Phreesia, Inc. (NYSE:PHR) CFO Sells $22,555.28 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 836 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $26.98, for a total value of $22,555.28. Following the transaction, the chief financial officer now owns 147,673 shares in the company, valued at $3,984,217.54. This trade represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Price Performance

Shares of Phreesia stock opened at $27.24 on Monday. The business has a 50 day moving average of $23.54 and a 200 day moving average of $22.83. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The company has a market cap of $1.58 billion, a PE ratio of -18.53 and a beta of 0.94. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.58) EPS. As a group, equities research analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Institutional Trading of Phreesia

Large investors have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C purchased a new position in shares of Phreesia in the 2nd quarter valued at approximately $4,078,000. Champlain Investment Partners LLC lifted its position in Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after buying an additional 97,847 shares during the period. Sei Investments Co. boosted its holdings in shares of Phreesia by 135.3% during the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after buying an additional 95,058 shares in the last quarter. Squarepoint Ops LLC grew its position in shares of Phreesia by 56.3% in the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock worth $5,308,000 after buying an additional 90,215 shares during the period. Finally, State Street Corp increased its stake in shares of Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after acquiring an additional 88,517 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PHR. Citigroup boosted their price objective on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Robert W. Baird decreased their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of Phreesia in a report on Friday, January 10th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.